New global guidelines warn against obesity drugs for children under 10

The World Health Organization issued a firm new guideline stating that obesity medicines, bariatric surgery, and weight‑management devices should not be used for children under ten years of age. The recommendation, voiced by Dr Luz De Rigil, WHO’s Director of Nutrition and Food Safety, underscores that treatment for this age group must rely on healthy eating and physical activity rather than pharmacological or surgical interventions. While many of the drugs are only licensed for older children and adolescents, some clinicians are prescribing them off‑label, and pharmaceutical firms are conducting trials in children as young as six, prompting the WHO to draw a clear line for younger patients.

The guidance arrives amid a dramatic rise in childhood obesity worldwide. Current estimates indicate that roughly 170 million children and adolescents are obese, including 70 million aged five to nine, a prevalence that has quadrupled since 1990 from 2 % to 8 %. In 2024, an additional 35 million children under five were classified as overweight. The health risks associated with early‑onset obesity are substantial, encompassing heightened chances of type 2 diabetes and other chronic conditions. WHO acknowledges that while drug and device therapies may be appropriate for older youths when lifestyle measures fail and the individual is mentally and physically prepared, the evidence base for such interventions in younger children remains insufficient.

WHO officials emphasized the need for caution and further research. Laurence Grummer‑Strawn, head of Nutrition and Food Safety Actions at the agency, warned that early exposure to GLP‑1 agonists or similar drugs lacks data on long‑term outcomes and raises questions about when treatment should cease and whether dietary habits can later be re‑established. The organization does not oppose clinical trials but stresses that any such studies must be rigorously evaluated. Digital tools like activity trackers and active‑play video games are mentioned as potentially useful adjuncts, though supporting evidence is limited. The WHO’s stance signals a conservative approach, urging health systems to prioritize lifestyle interventions for young children while monitoring emerging evidence on pharmacological options.

⚡ Effects Interpreter